News & Videos - DYNAVAX TECHNOLOGIES - English - Page 3

Dynavax Reports Second Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., Aug. 4, 2022 Q2 2022 total revenue of $256.5 million , up 386% from $52.8 million for Q2 2021 HEPLISAV-B ® vaccine net product revenue of $32.7 million, up 139% from $13.7 million for Q2 2021 CpG 1018 ® adjuvant net product revenue of $222.6 million , up 471% from $39.0 million for Q2 2021 On track for second consecutive year of profitability Conference call today at 4:30 p.m. ET / 1:30 p.m. PT EMERYVILLE,...

Dynavax to Report Second Quarter Financial Results and Host Conference Call on August 4, 2022 PR Newswire EMERYVILLE, Calif., July 21, 2022 EMERYVILLE, Calif. , July 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report second quarter financial results on Thursday, August 4, 2022 , after the U.S. financial markets close. Dynavax will host a conference call and live...

Dynavax to Present at the H.C. Wainwright Global Investment Conference PR Newswire EMERYVILLE, Calif., May 16, 2022 EMERYVILLE, Calif. , May 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022 . The on demand presentation will...

Dynavax Reports First Quarter 2022 Financial Results PR Newswire EMERYVILLE, Calif., May 5, 2022 First quarter 2022 total revenue of $114.0 million , up 37% from $83.3 million for Q1 2021 HEPLISAV-B ® vaccine net product revenue of $20.8 million , up 151% from $8.3 million for Q1 2021 CpG 1018® adjuvant net product revenue of $91.5 million , up 23% from $74.6 million for Q1 2021 Guidance reiterated for 2022 CpG 1018 revenue, operating expenses, and other costs On track for a second consecutive...

Dynavax to Report First Quarter 2022 Financial Results and Host Conference Call on May 5, 2022 PR Newswire EMERYVILLE, Calif., April 21, 2022 EMERYVILLE, Calif. , April 21, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report first quarter 2022 financial results on Thursday, May 5, 2022 , after the U.S. financial markets close. Dynavax will host a conference...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., April 5, 2022 EMERYVILLE, Calif. , April 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 28,250 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on April 1, 2022 ,...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., March 8, 2022 EMERYVILLE, Calif. , March 8, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 33,250 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 48,250 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., March 3, 2022 EMERYVILLE, Calif. , March 3, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted restricted stock units (RSUs) covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 1, 2022 ,...

Dynavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Full Year 2022 Financial Guidance - Record 2021 total revenue of $439 million, up from $47 million for 2020 -- Record full year HEPLISAV-B®net product revenue of $62 million -- Record full year CpG 1018® adjuvant net product revenue of $375 million, meeting previously...

Dynavax to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 28, 2022 PR Newswire EMERYVILLE, Calif., Feb. 16, 2022 EMERYVILLE, Calif. , Feb. 16, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company focused on developing and commercializing innovative vaccines, will report fourth quarter and full year 2021 financial results on Monday, February 28, 2022 , after the U.S. financial markets...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Feb. 2, 2022 EMERYVILLE, Calif. , Feb. 2, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 105,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 73,250 shares of Dynavax common stock as inducements to 11 newly-hired employees in connection...

Dynavax Highlights 2022 Priorities and Announces Initiation of Phase 1 Clinical Trial for Its Shingles Vaccine Candidate - Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 - Strong financial position supports investment in long-term growth drivers including pipeline expansion - Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022 PR Newswire...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Jan. 7, 2022 EMERYVILLE, Calif. , Jan. 7, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 94,000 shares of Dynavax common stock and restricted stock units (RSUs) covering an aggregate of 2,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with...

Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference PR Newswire EMERYVILLE, Calif., Jan. 5, 2022 EMERYVILLE, Calif. , Jan. 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer , Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022 . The on demand presentation will be...

COVID-19 Vaccine Developed by Biological E Using Dynavax's CpG 1018 Adjuvant Receives India DCGI Approval for Emergency Use - Further supports Dynavax's CpG 1018 adjuvant as an important adjuvant platform for vaccine development PR Newswire EMERYVILLE, Calif., Dec. 28, 2021 EMERYVILLE, Calif. , Dec. 28, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Biological E reported...

Elaine D. Sun Appointed to Dynavax Board of Directors PR Newswire EMERYVILLE, Calif., Dec. 14, 2021 EMERYVILLE, Calif. , Dec. 14, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines to protect the world against infectious diseases, today announced the appointment of Elaine Sun to its Board of Directors. "We are delighted to welcome Elaine to our Board of Directors. Her strategic, operational...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Dec. 2, 2021 EMERYVILLE, Calif., Dec. 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 58,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on December 1, 2021 at...

Dynavax to Present at the 4th Annual Evercore Virtual ISI HealthCONx Conference PR Newswire EMERYVILLE, Calif., Nov. 18, 2021 EMERYVILLE, Calif. , Nov. 18, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer , Chief Executive Officer, will participate in a virtual fireside chat at the 4th Annual Evercore virtual ISI HealthCONx Conference on Tuesday, November...

Dynavax Reports Third Quarter 2021 Financial Results - Third quarter 2021 total revenue of $108.3 million -- HEPLISAV-B net product revenue of $22.7 million -- CpG 1018® adjuvant product revenue of $84.3 million - Increased 2021 full-year CpG 1018 revenue guidance to be between $375 and $425 million - ACIP voted unanimously to recommend that all adults 19 to 59 years of age should receive hepatitis B vaccination - Conference call to be held today at 4:30 p.m. ET/1:30 p.m. PT PR Newswire...

Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire EMERYVILLE, Calif., Nov. 2, 2021 EMERYVILLE, Calif. , Nov. 2, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) today reported that it has granted nonstatutory stock options to purchase an aggregate of 5,000 shares of Dynavax common stock as inducements to 1 newly-hired employee in connection with commencement of employment with the Company. The stock options were granted on November 1, 2021 at...